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REVIEW
Abstract: Plant sterol-enriched foods are an effective dietary adjuvant in reducing
cardiovascular risk by lowering total cholesterol and low density lipoprotein-cholesterol (LDL-
C) in serum by up to ~15%. The mechanism of action of plant sterols is different from those
of 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) and thus their effect is additive.
Combining plant sterols with other dietary components known to reduce cholesterol in a
portfolio approach has proven to be most effective for reduction of hypercholesterolemia and
provide an alternative treatment option for clinicians. Plant sterol-enriched foods provides
clinicians with a relatively cheap, safe, and effective way to help patients manage their
cardiovascular risk.
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The problem of cardiovascular disease
Cardiovascular diseases (CVD), including stroke, coronary occlusion, ischemic
heart disease (IHD), atherosclerotic heart disease, vascular and coronary
thrombosis, is the leading cause of death in most Western societies. This has
wide public health implications. In 2002, CVD made up 16.7 million, or 29.2%
of total global deaths (WHO 2005). It is predicted that CVD will be the leading
cause of death in developing countries by 2010 (WHO 2005). Approximately
80% of CVD are prevalent in low and middle-income countries (WHO 2005). In
Australia, CVD are the most costly diseases for the health system and in 1993–
94, CVD accounted for $AU3719 million or 12% of total direct health system
costs in that year (AIHW 2004).
No authentic cause of atherosclerosis has been isolated, but is believed to be
multifactorial (Buja 1996). To date, etiological research has only established risk
factors which provide the basis for some efficient but incomplete means for
prevention. Most of this evidence relating to risk factors is epidemiologic and
therefore consists of statistical evidence for probability of evidence (Buja 1996).
The three factors most consistently associated with an increase in the incidence
of CVD include hypertension, hypercholesterolemia, and cigarette smoking. Other
modifiable risk factors include obesity, lack of exercise, hypertriglyceridemia
and low high-density lipoprotein-cholesterol (HDL-C) levels. There are also a
number of nonmodifiable risk factors such as male gender, diabetes mellitus,
family history of premature CVD, and the presence of definitive atherosclerosis.
There is considerable evidence that dietary saturated (and trans) fatty acids
lead to increases in blood levels of cholesterol, and ultimately to atherosclerosis.
In the past this has been the theoretical underpinning to many health-promoting
and dietary prevention strategies (Kwiterovich 1997). Initially, expert committees
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from major scientific associations such as the National
Heart, Lung and Blood Institute, and the American Heart
Association initiated clinical trials with the aim of decreasing
plasma cholesterol levels in an attempt to decrease the risk
of atherosclerotic disease (the diet–heart hypothesis)
(Haskell 2003).
Risk factors of cardiovascular
disease
The clinical manifestations of CVD are chronic arterial
obstructions or acute arterial occlusions in various territories,
which ultimately lead to the condition where there is an
inadequate supply of blood to the heart muscle, brain, or
visceral limbs leading to ischemia and in severe cases,
myocardial infarction (Ulbricht and Southgate 1991).
Atherosclerosis is a disease of the tunica intima (arterial
inner lining of the lumen) of the large and medium sized
arteries, characterized by the development of fibrous, fatty
deposits called plaques or atheromas (Zeman 1991). These
atheromas eventually become calcified, rendering them rigid
and narrow.
As yet, the pathogenesis is only partially understood.
The development of an atheroma (or plaque) in the intima
of the major arteries marks the pathogenesis of
atherosclerosis. Arterial wall abnormalities, blood
composition abnormalities, and hemodynamic alterations
are generally accepted to be causative (Virchow’s triad) (von
Baeyer et al 2003). There is strong support for a causative
relationship between hypercholesterolemia and
atherosclerosis originally evidenced by the premature
development of CVD in younger individuals with familial
hypercholesterolemia (Ross 1986). There is also direct
evidence from animal models of the effect of elevated low-
density lipoprotein-cholesterol (LDL-C) on atherogenesis
(Ross 1986) initiating the cascade of events eventually
leading to atherosclerosis (Steinberg et al 1989). Shear-stress
induced micro injuries of the endothelium in
hemodynamically compromised regions together with local
coagulation activation associated with microinflammation
of the plaque are currently thought to cause plaque rupture
(von Baeyer et al 2003). The resultant local clot formation
is the ultimate reason for heart failure. This has been
confirmed in a number of large trials showing a combined
reduction of cardiac deaths and non-fatal myocardial
incidents in post infarction patients by approximately 35%
through the use of cholesterol-lowering medications
(Anonymous 1994; Sacks et al 1996).
Current dietary guidelines – the
use of plant sterols
The Adult Treatment Panel (ATPIII) of the US National
Cholesterol Education Program (NCEP) recommend as part
of their therapeutic lifestyle changes for the reduction of
CVD risk, a diet which contains 25%–35% of total calories
from fat (<7% saturated fatty acids (SFA), up to 10%
polyunsaturated fatty acids (PUFA), and up to 20%
monounsaturated fatty acids (MUFA), 50%–60% of total
calories from carbohydrates (CHO), ~15% of total energy
from protein (PRO), <200 mg cholesterol/day, dietary fibre
20–30 g/day and total energy to be balanced with energy
expenditure to maintain desirable body weight or prevent
weight gain (NCEP 2001). More recently there is a
recommendation to include 2 g per day of plant sterols into
the diet for those with elevated serum LDL-C (NCEP 2001)
in response to the growing amount of evidence showing
significant cholesterol-lowering from plant sterol/stanol-
enriched margarines. The use of plant sterol-enriched
products is also recommended by the International
Atherosclerosis Society (IAS 2003) and the National Heart
Foundation of Australia (NHF 2001).
The most common are unsaturated plant sterols β-
sitosterol, campesterol, and stigmasterol and the saturated
sitostanol and campestanol (Kochhar 1983). Research over
the past decade has focused on the esterified form of plant
sterols which is added to food products such as margarine
for reasons of greater product stabilization, although free-
forms of plant sterols have been studied in yoghurt
(Thomsen et al 2004). Plant sterols reduce the absorption
of both dietary and biliary cholesterol from the intestinal
tract by 30%–50% (Jones et al 2000). The exact mechanism
is yet to be elucidated; it is generally assumed that the
presence of increased quantities of plant sterols in the gut
lowers the micellar solubility of cholesterol, therefore
lowering the amount of cholesterol available for absorption
(Jones et al 2000) . Recent advancements in food technology
have seen the emergence of food products such as margarine,
milk, yoghurt, and cereal products being enriched with plant
sterols/stanols and promoted as a food which can help lower
serum cholesterol.
Efficacy of plant sterol-enriched
products
The results of dietary interventions aimed at reducing total
serum cholesterol have been largely ineffectual. It has been
suggested that dietary advice to individuals produced smallVascular Health and Risk Management 2006:2(2) 159
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reductions in total cholesterol concentration (less than 4%),
rendering it of little value in clinical management (Ramsay
et al 1991). Tang et al (1998) published a systematic review
of 19 randomized, controlled dietary intervention trials under
free-living conditions aimed at lowering total cholesterol.
The overall weighted mean reduction in blood cholesterol
across all dietary comparisons was only 5.3%, using trials
of at least six months duration. Although this may translate
into a 5%–10% reduction of CVD in a 10-year period,
compared with the effectiveness of the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG CoA) inhibitors (statins:
the most commonly used drugs for lowering serum
cholesterol), dietary interventions risked being undervalued
as a front line therapy for the management of serum
cholesterol if it wasn’t for the emergence of plant stanol/
sterol-enriched functional foods.
In 57 trials, the efficacy of plant sterol esters and plant
stanol esters in reducing mean total cholesterol (TC) and
LDL-C was studied in normocholesterolemic,
hypercholesterolemic, or diabetic individuals (n=3609)
(Normén et al 2005). When plant sterols/stanols are added
to foods such as margarine with an average dose of 2.4 g/
day (standard deviation [SD] ± 1.3 g/day), lowering was
9.9% (SD ± 3.9%) for LDL-C (Normén et al 2005). It has
been shown that there is no significant difference in the
efficacy between plant sterols and plant stanols when they
are esterified, which is the form added to foods (Hallikainen
et al 2000). Most of these studies used esterified plant sterols
in margarines. Further studies have investigated the
cholesterol-lowering effects in different food vehicles such
as milk, yoghurt, bread, and cereal. Clifton and colleagues
(Clifton, Noakes, Sullivan, et al 2004) have concluded that
serum total and LDL-C were significantly lowered when
plant sterols were added to: milk (8.7% and 15.9%) and
yoghurt (5.6% and 8.6%), but significantly less when added
to bread (6.5%) and cereal (5.4%), while other investigators
have made similar observations using yoghurt (Volpe et al
2001; Mensink et al 2002), and milk (Thomsen et al 2004).
Effectiveness of plant sterol-
enriched products
Most studies to date have been in controlled settings using
willing volunteers and providing subjects with plant sterol-
or stanol-enriched products. It is important to evaluate the
effectiveness of this treatment in a clinical or ‘free-living’
context. Effectiveness answers the question of compliance,
ie, do subjects comply with the therapy to ensure that the
effect is still observed. Whilst it may be correct to assume
that efficacy in controlled settings often equates to
effectiveness with therapeutic drugs, with functional foods,
issues relating to the belief in the benefit of use, taste,
preference, and price may affect consumption and ultimately
compliance (Anderson et al 1998; Povey et al 2001). Given
the reported inconsistency in consumption of these products
(Simojoki et al 2004), there have been recommendations to
replicate these results in subjects who assemble the diets
for themselves on a routine basis, thus determining the true
effectiveness of this strategy in the clinical setting (Jenkins
et al 2003). In addition, the net effect on the whole diet
needs to be considered in those who select functional foods,
given the importance of other dietary aspects such as
restricting saturated fat and cholesterol and increasing n-3
fatty acids in reducing CVD risk (Schaefer 2002). In a
clinical trial with hospital outpatients, using the number-
needed-to-treat index, it was demonstrated, that for each
2.8 patients counseled with routine prescription of plant
stanol/sterols, one additional patient would obtain a
reduction in cholesterol by ≥15% compared with
conventional treatment (Patch et al 2005). What was
demonstrated in a controlled environment can now be safely
extrapolated in a free-living context.
Safety
There have been concerns raised over the reduced absorption
of some fat soluble vitamins from intake of plant sterols.
Plant sterols and stanols have been shown to reduce β-
carotene, α-carotene, and vitamin E levels by around 25%,
10%, and 8% respectively (Gylling and Miettinen 1999;
Hallikainen et al 1999; Hendriks et al 1999). This appears
to be more pronounced at higher levels of intake (6.6 g/day),
however this does not provide any additional cholesterol-
lowering benefits beyond what would be obtained from an
intake of around 3 g/day (Clifton, Noakes, Ross, et al 2004).
In addition, Noakes et al (2002) found that a reduced
absorption can be abated by an increased consumption of
carotene-containing vegetables within current dietary
recommendations.
There have been concerns regarding the possible
atherogenic effects of plant sterols in certain individuals.
Most recently, Miettinen et al (2005) concluded that statin
treatment was associated with an increase in plant sterols
absorption and also arterial plaque. In contrast, recent
experimental models that have tested whether elevated
plasma levels of plant sterols were associated withVascular Health and Risk Management 2006:2(2) 160
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atherosclerosis in genetically modified mice and in middle-
aged men and women found no association (Wilund et al
2004). In mice with inactivation of adenosine 5'-triphosphate
(ATP)-binding cassette leading to >20-fold higher plasma
levels of plant sterols, no significant differences in aortic
lesion area compared with controls were found (Wilund et
al 2004). Furthermore, in a study consisting of 2542 men
and women to determine the relationship between plasma
plant sterols and atherosclerosis, no association was found
(Wilund et al 2004). The role of dietary plant sterols in the
development of atherosclerotic plaque is unclear and further
research is warranted to determine its safety in subgroups
of the population.
The daily supply of plant sterols in a typical ‘Western
diet’ amounts to an average of 150–400 mg per person (SCF
2002). Human and animal studies have shown that plant
sterol and stanol esters are non-toxic (Ayesh et al 1999;
Baker et al 1999; Hepburn et al 1999; Waalkens-Berendsen
et al 1999; Westrate et al 1999). Since 1997, when the first
plant sterol containing margarine was introduced to the
European market, many more applications have been lodged
to add plant sterols to dairy products, cheeses, bakery
products, sausages, plant oils, and other products (Kuhlmann
et al 2005). Concerns have been expressed regarding the
potential excessive consumption of plant sterols as it cannot
be excluded that high intakes might induce undesirable
effects. A study in Germany, based on a dietary simulation
method, demonstrated that if a range of products are
available at an enrichment amount delivering 2 g of plant
sterols per serve, it resulted in an intake maximum of 13 g/
day (Kuhlmann et al 2005). A model designed to stimulate
such a scenario in the Finnish populations also revealed that
an intake of 4–9 g could be achieved when alternative plant
sterol containing products to margarine were added to the
food supply (Raulio et al 2001). However, a cohort of 29 772
plant stanol ester margarine users based on a compilation
of 15 surveys conducted by the National Public Health
Institute in Finland between 1996–2000 concluded that
sterol-enriched margarine was used by persons for whom
they were designed and in the way it was intended (Simojoki
et al 2005).
Plant sterols in combination with
medications and other functional
foods
There is growing support for plant sterol use as an
adjuvant to current pharmaceutical interventions with the
aim of preventing CVD. Statins are most effective in
ameliorating intrinsic high cholesterol synthesis
(Thompson et al 2002), whereas plant sterols are most
effective in individuals with high intrinsic cholesterol
absorption from the gastrointestinal tract (Jandacek et al
1977). Statins differ in their lipid-lowering potency, with
cholesterol reduction ranging from 32% and 41% for TC
and LDL-C respectively on a low dose statin (10 mg/day
of Rosuvastatin) to 42% and 55% respectively for a high
dose statin (40 mg/day Rosuvastatin) (Jones et al 2003).
There have been five randomized, controlled trials
combining the use of plant sterols and statin medications
(Vanhanen 1994; Gylling et al 1997; Miettinen et al 2000;
Neil et al 2001; Simons 2002) which show that in
combination plant sterols have an additive effect of 4.5%
± 2.4% per g sterols. This translates to an additional risk
reduction of cardiovascular events by ~9%–14% using
risk modelling equations (Keys et al 1957) and there have
been no reported nutrient–drug interactions. In a meta-
analysis the predicted CVD risk reduction from including
plant sterol in the diet was up to 20% in the longer term
(Katan et al 2003). With the escalating cost associated
with statin medications, plant sterol-enriched products
provide a clinical and financially viable strategy. In what
is a world first, a Dutch health insurer (VGZ) has begun
reimbursing members (€40 worth of products each year,
or about US$52 annually) for buying heart-healthy foods
such as margarine, yogurt, and milk enriched with
cholesterol-lowering plant sterols (Harding 2004).
More recently, it has been suggested that newer dietary
approaches combining a number of cholesterol-lowering
foods may offer another option to routine medication
prescription. There is now enough evidence for the US
Food and Drug Administration (FDA) to permit health
claims for coronary heart disease risk reduction and
dietary plant sterols, oat β-glucan, psyllium, soy protein,
and nuts (Jenkins et al 2005). Earlier last year, an
important study was published that investigated the
effectiveness of a combining all of these foods in a
portfolio approach to dietary intervention. After 1 month’s
intervention, participants taking lovastatin (20 mg/day)
had a mean (SE) decrease in LDL-C of 30.9% (3.6%)
(p<0.001) compared with 28.6% (3.2%) (p<0.001) for
the portfolio diet group, with no significant difference
between the two groups (Jenkins et al 2005). This has
practical significance as this is the first report showing
that a ‘whole of diet’ approach incorporating plant sterols
increases the effectiveness of the diet as a treatment forVascular Health and Risk Management 2006:2(2) 161
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hypercholesterolemia and is as effective as a low dose
statin therapy.
Conclusions
The inclusion of plant sterols in a variety of foods provides
consumers and clinicians with alternatives in the
management of hypercholesterolemia. Used alone in the
diet, or as an adjuvant to drug therapy, or in combination
with other functional food components, plant sterol enriched
products are effective at reducing serum total and LDL-C.
There are no risks associated with their use and widespread
acceptance has the potential to reduce the costs associated
with an over-dependence on pharmacological approaches
to cholesterol management.
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